Diabetes Clinical Trials in Los Angeles

View 344 new treatments for Diabetes in Los Angeles, CA. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.

Tirzepatide for Type 2 Diabetes

Eli Lilly Clinic, Panorama City + 10 more

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.Show More

Verified

Recruiting

No Placebo Trial

Phase 4
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

CagriSema for Type 2 Diabetes

Novo Nordisk Clinic, Panorama City + 5 more

This trial tests CagriSema, a combination of semaglutide and cagrilintide, in people with type 2 diabetes. It aims to see if it can better manage blood sugar levels and reduce body weight by increasing insulin and reducing hunger. Semaglutide is known for lowering blood glucose levels and reducing appetite.Show More

Verified

Recruiting
Phase 3
Est. 4 - 6 Weeks
Clinical Transparency (dept. 2834)
Study Director

Lanifibranor for Nonalcoholic Steatohepatitis (NASH)

Inventiva Clinic, Panorama City + 14 more

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Verified

Recruiting
Phase 3
Est. 3 - 12 Weeks
Sven Francque, MD
Principal Investigator

INV 202 for Diabetic Kidney Disease

Inversago Clinic, Irvine + 12 more

This trial tests a new drug called INV-202 in adults with Diabetic Kidney Disease caused by Type 1 or Type 2 diabetes. The goal is to see if the drug is effective, safe, and well-tolerated, and how it behaves in the body.Show More

Verified

Recruiting
Phase 2
Est. 3 - 12 Weeks
Glenn Crater, MD
Study Director

CIN-102 for Gastroparesis

CinDome Clinic, Corona + 8 more

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants will go through the following schedule: Screening period (1-2 visits) Lead-in period (1 visit) Will complete a Gastric Emptying Breath Test (GEBT) Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation 12-week treatment period (5 visits) Study drug taken twice daily by mouth Will complete daily diaries and other PROs as described in protocol 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: Drug- CIN-102 Dose 1 Drug- CIN-102 Dose 2 Drug- PlaceboShow More

Verified

Recruiting
Phase 2
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

BMF-219 for Type 2 Diabetes

Biomea Fusion Clinic, Montclair + 3 more

This trial tests a new pill called BMF-219 that targets a protein named menin. It includes healthy adults and those with Type 2 Diabetes to see if it helps control blood sugar levels.Show More

Verified

Recruiting

No Placebo Trial

Phase 1 & 2
Est. 4 - 6 Weeks
Stephen Morris, MD
Study Director

Doravirine for HIV

Research Clinic, Los Angeles + 2 more

This trial is testing doravirine, an HIV medication, in people with HIV who have abnormal cholesterol levels. The goal is to see if doravirine can help control HIV and improve cholesterol and heart health. Doravirine is a newly-approved antiretroviral.Show More
Recruiting

No Placebo Trial

Phase < 1
Est. 3 - 12 Weeks
Theodoros Kelesidis, MD PHD
Principal Investigator

ILUVIEN® Implant for Diabetic Macular Edema

Alimera Sciences Clinic, Laguna Hills + 4 more

This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Samer Kaba, MD
Study Chair

Tirzepatide for Atherosclerosis in Type 2 Diabetes

Research Clinic, Torrance + 1 more

A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
Matthew A Budoff, MD
Principal Investigator

Metformin for Prediabetes

Research Clinic, West Los Angeles + 2 more

This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Gregory G. Schwartz, PhD MD
Study Chair
Page 1 of 18

Frequently Asked Questions

How much do diabetes clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do diabetes clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across diabetes trials in Los Angeles, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for diabetes patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.